Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02384395 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02384395 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants.
The verdict
NCT02384395, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
Interventions
- DRUG Dolutegravir 50 mg
- DRUG Lamivudine 300 mg
- DRUG Abacavir 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-09-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02384395
The ClinicalTrials.gov registry entry for NCT02384395 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dolutegravir 50 mg is the first listed.
NCT02384395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02384395 about?
NCT02384395 is a clinical study titled "Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection". This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
What is the current status of trial NCT02384395?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2015-09. Estimated completion is 2021-09-17.
What interventions are being tested in trial NCT02384395?
The interventions under investigation include: Dolutegravir 50 mg (DRUG), Lamivudine 300 mg (DRUG), Abacavir 600 mg (DRUG).
Who is sponsoring clinical trial NCT02384395?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.